Adam S Kittai1, Matthew Lunning2, Alexey V Danilov3. 1. Knight Cancer Institute, Oregon Health & Science University, 2720 SW Moody Ave, #2106, Portland, OR, 97201, USA. 2. Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. 3. Knight Cancer Institute, Oregon Health & Science University, 2720 SW Moody Ave, #2106, Portland, OR, 97201, USA. danilov@ohsu.edu.
Abstract
PURPOSE OF REVIEW: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. RECENT FINDINGS: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.
PURPOSE OF REVIEW: Clinicians continue to utilize prognostic biomarkers, such as expression of CD38 and ZAP-70, IGHV mutational status, cytogenetic abnormalities, and genomic aberrations in TP53, to guide prognosis and treatment of patients with CLL. These biomarkers have been validated with standard chemoimmunotherapy. Here, we discuss whether these biomarkers maintain their prognostic significance in the era of targeted therapy. RECENT FINDINGS: Multiple phase 3 clinical trials have now proven improved efficacy of targeted therapy over traditional chemoimmunotherapy. We now have ample prospective data using targeted therapy to critically evaluate whether prior prognostic biomarkers remain relevant. High-risk features do not have the same magnitude of effect on clinical outcomes in the era of targeted therapy when compared to chemoimmunotherapy. Aberrations in TP53 continue to predict inferior outcomes. More research is needed to determine what features confer poor prognosis when targeted therapy is used to treat CLL.
Authors: Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps Journal: N Engl J Med Date: 2004-08-26 Impact factor: 91.245
Authors: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Stephan Stilgenbauer; Andrea Schnaiter; Peter Paschka; Thorsten Zenz; Marianna Rossi; Konstanze Döhner; Andreas Bühler; Sebastian Böttcher; Matthias Ritgen; Michael Kneba; Dirk Winkler; Eugen Tausch; Patrick Hoth; Jennifer Edelmann; Daniel Mertens; Lars Bullinger; Manuela Bergmann; Sabrina Kless; Silja Mack; Ulrich Jäger; Nancy Patten; Lin Wu; Michael K Wenger; Günter Fingerle-Rowson; Peter Lichter; Mario Cazzola; Clemens M Wendtner; Anna M Fink; Kirsten Fischer; Raymonde Busch; Michael Hallek; Hartmut Döhner Journal: Blood Date: 2014-03-20 Impact factor: 22.113
Authors: Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-06-24 Impact factor: 22.113
Authors: Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245
Authors: Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd Journal: Lancet Oncol Date: 2013-12-10 Impact factor: 41.316
Authors: Jennifer R Brown; John C Byrd; Steven E Coutre; Don M Benson; Ian W Flinn; Nina D Wagner-Johnston; Stephen E Spurgeon; Brad S Kahl; Celeste Bello; Heather K Webb; Dave M Johnson; Sissy Peterman; Daniel Li; Thomas M Jahn; Brian J Lannutti; Roger G Ulrich; Albert S Yu; Langdon L Miller; Richard R Furman Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: Scott Best; Vi Lam; Tingting Liu; Nur Bruss; Adam Kittai; Olga V Danilova; Susan Murray; Allison Berger; Nathan D Pennock; Evan F Lind; Alexey V Danilov Journal: Leukemia Date: 2020-03-16 Impact factor: 11.528